A landscape of synergistic drug combinations in non-small-cell lung cancer
Nair, N. U.; Greninger, P.; Friedman, A.; Amzallag, A.; Cortez, E.; Sahu, A. D.; Lee, J. S.; Dastur, A.; Egan, R. K.; Murchie, E.; Crowther, G. S.; McClanaghan, J.; Boisvert, J.; Damon, L.; Ho, J.; Tam, A.; Garnett, M. J.; Engelman, J. A.; Haber, D. A.; Ruppin, E.; Benes, C. H.
Show abstract
Targeted therapeutics have advanced cancer treatment, but single agent activity remains limited by de novo and acquired resistance. Combining targeted drugs is broadly seen as a way to improve treatment outcome, motivating the ongoing search for efficacious combinations. To identify synergistic targeted therapy combinations and study the impact of tumor heterogeneity on combination outcome, we systematically tested over 5,000 two drug combinations at multiple doses across a collection of 81 non-small cancer cell lines. Both known and novel synergistic combinations were identified. Strikingly, very few combinations yield synergy across the majority of cell line models. Importantly, synergism mainly arises due to sensitization of single agent resistant models, rather than further sensitize already sensitive cell lines, frequently via dual targeting of a single or two highly interconnected pathways. This drug combinations resource, the largest of its kind should help delineate new synergistic regimens by facilitating the understanding of drug synergism in cancer.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pathway activation model for personalized prediction of drug synergy 97%
- The transcriptomic response of cells to a drug combination is more than the sum of the responses to the monotherapies 96%
- A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy 96%
Similar papers in this journal
- Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens 98%
- Mechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance 93%
- Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response 93%
Similar papers in this journal
- Community assessment of cancer drug combination screens identifies strategies for synergy prediction 95%
- Epigenetic modulation reveals differentiation state specificity of oncogene addiction 94%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 94%
Similar papers in this journal
- Guiding ATR and PARP inhibitor combinations with chemogenomic screens 96%
- Drug GRADE: an integrated analysis of population growth and cell death reveals drug- specific and cancer subtype-specific response profiles 95%
- Genetic dependencies associated with transcription factor activities in human cancer cell lines 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.